Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.
- We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.
- Emergent is one of four companies providing hyperimmune globulin products for the trial, which plans to enroll approximately 500 patients across U.S. and international clinical trial sites.
- The main goal of the trial is to compare the health status of participants treated with hyperimmune globulin plus remdesivir with participants treated with a placebo plus remdesivir.
- Using its established hyperimmune platforms, Emergent is developing two investigational plasma-based treatments - COVID-19 Human Immune Globulin (COVID-HIG) and COVID-Equine Immune Globulin (COVID-EIG).